Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: Final results of a single-centre phase II trial

British Journal of Haematology

Volumn 150, Issue 2, 2010, Pages 226-229

  Govi, Silvia ^a   Dognini, Giuseppina P ^b   Licata, Giada ^a   Crocchiolo, Roberto ^a   Resti, Antonio Giordano ^a   Ponzoni, Maurilio ^a   Ferreri, Andrés J M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b TREVIGLIO HOSPITAL   (Italy)

Author keywords

anti neoplastic activity; clarithromycin; conjunctival lymphoma; extranodal marginal zone lymphoma; immunomodulator

Indexed keywords

ANTINEOPLASTIC AGENT; CLARITHROMYCIN;

ADULT; AGED; BONE MARROW; BREAST; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; KIDNEY; LETTER; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; ORBIT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; STOMACH; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77954323703     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08179.x     Document Type: Letter

References (10)

1. Aoki, D., Ueno, S., Kubo, F., Oyama, T., Sakuta, T., Matsushita, K., Maruyama, I. Aikou, T. (2005) Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. Anticancer Research, 25, 133 138.
2. Arima, N. Tsudo, M. (2003) Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy. British Journal of Haematology, 120, 790 792.
3. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-hodgkin's lymphomas. NCI sponsored international working group. Journal of Clinical Oncology, 17, 1244.
4. Ferreri, A.J., Guidoboni, M., Ponzoni, M., De Conciliis, C., Dell'Oro, S., Fleischhauer, K., Caggiari, L., Lettini, A.A., Dal Cin, E., Ieri, R., Freschi, M., Villa, E., Boiocchi, M. Dolcetti, R. (2004) Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. Journal of the National Cancer Institute, 96, 586 594.
5. Ferreri, A.J., Ernberg, I. Copie-Bergman, C. (2009) Infectious agents and lymphoma development: molecular and clinical aspects. Journal of Internal Medicine, 265, 421 438.
6. Hamada, K., Mikasa, K., Yunou, Y., Kurioka, T., Majima, T., Narita, N. Kita, E. (2000) Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy, 46, 49 61.
7. Matsumoto, T. Iida, M. (2005) Extra-gastric lymphoma of MALT type and H. pylori eradication. Nippon Rinsho.Japanese Journal of Clinical Medicine, 63 (Suppl 11 308 311.
8. Niesvizky, R., Jayabalan, D.S., Christos, P.J., Furst, J.R., Naib, T., Ely, S., Jalbrzikowski, J., Pearse, R.N., Zafar, F., Pekle, K., Larow, A., Lent, R., Mark, T., Cho, H.J., Shore, T., Tepler, J., Harpel, J., Schuster, M.W., Mathew, S., Leonard, J.P., Mazumdar, M., Chen-Kiang, S. Coleman, M. (2008) BiRD (biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood, 111, 1101 1109.
9. Tabbara, K.F., al-Kharashi, S.A., al-Mansouri, S.M., al-Omar, O.M., Cooper, H., el-Asrar, A.M. Foulds, G. (1998) Ocular levels of azithromycin. Archives of Ophthalmology, 116, 1625 1628.
10. Wakasugi, H., Yano, I., Ito, T., Hashida, T., Futami, T., Nohara, R., Sasayama, S. Inui, K. (1998) Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clinical Pharmacology and Therapeutics, 64, 123 128.